Moberg Pharma (MOB) Investor presentation summary

Product overview and innovation

• TerclaraⓇ is a novel topical terbinafine treatment for mild to moderate nail fungus in adults, designed for direct nail application and not requiring nail filing or lacquer removal.

• Delivers high concentrations of terbinafine to the nailbed with significantly lower systemic exposure compared to oral treatments.

• Features a patented keratolytic carrier that promotes visible nail improvement and is protected by global patents until 2032.

Clinical efficacy and safety

• Achieved a 76% mycological cure rate in Phase 3 studies, outperforming or matching oral and topical competitors.

• Demonstrated high safety and tolerability, with earlier onset of cure compared to oral terbinafine.

• Primary endpoints met in both EU and North American Phase 3 trials, supporting EU approval.

Market performance and positioning

• Approved in 13 European countries, with both OTC and Rx status depending on the market.

• Rapidly became market leader in Sweden and Norway, driving category growth and achieving significant value and volume shares.

• Awarded 'Launch of the Year' in Sweden and nominated in Norway by major pharmacy chains.

• Positioned as a premium product due to superior cure rates and user benefits.